Cosmo Pharmaceuticals Nv · SIX:COPN
Cosmo Pharmaceuticals Nv — Investor Presentation (September 2020)
22 slides from Cosmo Pharmaceuticals Nv's investor presentation, Sep 16, 2020
Slide 1: Corporate Presentation
Corporate Presentation September 16, 2020 Cosmo Pharmaceuticals
Slide 2: Safe Harbour
SAFE HARBOUR This presentation may include forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. The inclusion of forward-looking statements should not be regarded as a representation by Cosmo that any of its p
Slide 3: Agenda
A G E N DA 01 OVERVIEW 02 PRODUCTS UPDATE 03 2020 OUTLOOK AND PRIORITIES 04 QUESTIONS AND ANSWERS Cosmo Pharmaceuticals 3 Corporate Presentation - September 16, 2020
Slide 4: Cosmo Pharmaceuticals N.V. at a glance
FY20 Revenue guidance CO S M O P H A R M A C E U T I C A L S N .V. €52 - €56 million FY20 Operating Profit guidance €2 - €8 million Market Cap1 CHF 1,338.3 million Net Cash2 €238.4 million Employees 46.56% Stake in 261 Cassiopea at IPO offer price & rights 19.60% stake in RedHill at cost $47.2m offe
Slide 5: Providing solutions for colon diseases
CO S M O P H A R M A C E U T I C A L S N .V. Providing solutions for colon diseases 3 marketed Stakes in other therapeutics pharma Lialda/Mezavant companies: Uceris/Cortiment Aemcolo/RelaFalk 2 marketed 46.56% Cassiopea medtech products 19.60% RedHill Eleview 20.52% Acacia Pharma GI Genius (EU) 7.91
Slide 6: Strategy Going Forward
S T R AT EGY G O I N G FO RWA R D Following delay in approval of MB MMX in the U.S. Cosmo decided to shift strategy to: 01 02 Enter into partnerships with selective players in exchange of Develop new product equity stake and/or opportunities with milestones/royalties or partners combination of both
Slide 7: Products Update
PRODUCTS UPDATE Cosmo Pharmaceuticals 7 Corporate Presentation - September 16, 2020
Slide 8: Products Update
P RO D U C T S U P DAT E Methylene Blue MMX • The European Commission approved Methylene Blue MMX for the visualisation of colorectal lesions during colonoscopies in August. The Centralized European licence will be effective simultaneously in all EU Member States as well as in the European Economic
Slide 9: Products Update - Continued
P RO D U C T S U P DAT E - CO N T I N U E D Byfavo™ • Byfavo™ was approved by the FDA in July, this follows the sub-licensing of Byfavo™ to Acacia Pharma plc in January in an equity for product deal. GI Genius™ • Sales in Europe commenced at the end of 2019, however the pandemic is impacting sales.
Slide 10: Products Update - Continued
P RO D U C T S U P DAT E - CO N T I N U E D Aemcolo™ • The Italian Agenzia del Farmaco (AIFA) granted Marketing Authorization to Stadmycin™ (Rifamycin SV MMX) in July • The Aemcolo™ Phase II proof of concept study in IBS-D progressed, the pandemic is slowing down recruitment however we expect to com
Slide 11: Development Pipeline
D E V E LO P M E N T P I P E L I N E PRODUCT INDICATION PH I PH II PH III Aemcolo™ IBS-D Acute Uncomplicated Diverticulitis* Small Intestine BacteriaI Overgrowth (SIBO)* Minimal Hepatic Encephalopathy* Byfavo™ Procedural Sedation APPROVED Lesion detection during Methylene Blue MMX colonoscopy - Euro
Slide 12: Acacia Pharma Deal
A C A C I A P H A R M A D EA L • Acacia Pharma is an English company with U.S. operations listed on Euronext (EURONEXT: ACPH) run by a management team highly experienced in U.S. hospital sales • Byfavo™ was sub-licensed to Acacia with Acacia taking over all marketing activities, development responsi
Slide 13: Acacia Pharma Deal
A C A C I A P H A R M A D EA L • In addition, in January Cosmo also put loan facilities of €35m in place of which €10m was available for drawdown upon approval of Barhemsys® and a further €25m became available for drawdown upon approval of Byfavo™ • In February Barhemsys® was approved by the FDA and
Slide 14: H1 2020 Financial Highlights
H1 2020 FINANCIAL HIGHLIGHTS Cosmo Pharmaceuticals 14 Corporate Presentation - September 16, 2020
Slide 15: H1 2020 Financial Highlights
H1 2020 FINANCIAL HIGHLIGHTS • Revenue €25.9m vs €21.5m last year • Net expenses reduced by 40.0% to €23.2m mainly as a result of the restructuring of our U.S. organisation in 2019 and other income recorded as a result of sub-license deal with Acacia • Operating profit of €2.7m vs operating loss of
Slide 16: Income Statement - Revenue
I N CO M E S TAT E M E N T - R E V E N U E • Revenue €25.9m vs €21.5m last year • Lialda/Mesavant/Measvancol revenue increased by €2.9 million to €11.7m mainly due to increase in U.S. sales • Uceris income was €2.5m (H1 2019: €4.6m), net sales by Bausch were US$16.3m (H1 2019: US$32.5m) • Cortiment
Slide 17: Statement of Financial Position - Summary
S TAT E M E N T O F F I N A N C I A L P O S I T I O N – S U M M A RY EUR 1,000 30 Jun 20 31 Dec 19 Change Cash and cash equivalents and investments in funds 238,456 268,209 (29,753) Other current & non-current assets 358,161 316,951 41,210 Liabilities (191,177) (191,427) (250) Total Equity 405,440 3
Slide 18: 2020 Outlook & Key Priorities
2020 OUTLOOK & KEY PRIORITIES Cosmo Pharmaceuticals 18 Corporate Presentation - September 16, 2020
Slide 19: FY20 Guidance Maintained
F Y 2 0 G U I DA N C E M A I N TA I N E D Coronavirus pandemic • Notwithstanding the coronavirus pandemic our production facilities continue to operate, we continue to ship our products and the inputs required for our operations continue to be received. • Measures remain in place to protect the heal
Slide 20: Upcoming Milestones
U P CO M I N G M I L ES TO N ES 2020 H2 Key priorities for 2020 • Progress the U.S. trial for GI Genius™ Q4 • Commence the Methylene Blue MMX confirmatory Phase III trial GI Genius™ Progress trial • Conclude our Aemcolo™ phase II IBS- Aemcolo™ D trial Phase II IBS-D results • Progress our product pi
Slide 21: Thank You
THANK YOU Cosmo Pharmaceuticals 21 Corporate Presentation - September 16, 2020
Slide 22: Cosmo Pharmaceuticals NV contact details
Cosmo Pharmaceuticals NV Riverside II Sir John Rogerson’s Quay Dublin 2, Ireland media@cosmopharma.com Mr. Alessandro Della Cha, CEO adellacha@cosmopharma.com Mr. Niall Donnelly, CFO ndonnelly@cosmopharma.com +353 1 817 03 70 22 Corporate Presentation - September 16, 2020
Cosmo Pharmaceuticals — Investor Presentation (September 2020) on 6ix